These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15960550)

  • 1. Incorporation of uncertainty in health economic modelling studies.
    O'Hagan A; McCabe C; Akehurst R; Brennan A; Briggs A; Claxton K; Fenwick E; Fryback D; Sculpher M; Spiegelhalter D; Willan A
    Pharmacoeconomics; 2005; 23(6):529-36. PubMed ID: 15960550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.
    Nuijten MJ
    Pharmacoeconomics; 2004; 22(12):759-69. PubMed ID: 15294010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incorporation of potential confounding variables in Markov models.
    Nuijten MJ; Rutten F
    Pharmacoeconomics; 2003; 21(13):941-50. PubMed ID: 12959626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease.
    Postma MJ; Boersma C
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):1-4. PubMed ID: 22142151
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An introduction to the methods of cost-effectiveness analysis.
    Drug Ther Bull; 2012 Jul; 50(7):81-4. PubMed ID: 22789768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.
    Dams J; Bornschein B; Reese JP; Conrads-Frank A; Oertel WH; Siebert U; Dodel R
    Pharmacoeconomics; 2011 Dec; 29(12):1025-49. PubMed ID: 22077577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian Solutions for Handling Uncertainty in Survival Extrapolation.
    Negrín MA; Nam J; Briggs AH
    Med Decis Making; 2017 May; 37(4):367-376. PubMed ID: 27281336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques.
    Nuijten MJ; Rutten F
    Pharmacoeconomics; 2002; 20(12):855-67. PubMed ID: 12236807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision-analytical modelling in health-care economic evaluations.
    Sun X; Faunce T
    Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An introduction to Markov modelling for economic evaluation.
    Briggs A; Sculpher M
    Pharmacoeconomics; 1998 Apr; 13(4):397-409. PubMed ID: 10178664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
    Mil'chakova AE; Popov GR; Bykov AV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194
    [No Abstract]   [Full Text] [Related]  

  • 17. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
    Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.